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Abstract
Background: Hyperlipidemia associated with obesity is closely related to the development of atherosclerosis. Both
n-3 polyunsaturated fatty acids (PUFAs) and long-chain monounsaturated fatty acids (MUFAs; i.e., C20:1 and C22:1
isomers) supplementation modulate risk factors for metabolic syndrome via multiple mechanisms, including the
restoration of impaired lipid metabolism. We therefore examined the effects of pollock oil, which contains a
considerable amount of n-3 PUFAs as well as long-chain MUFAs, on plasma hyperlipidemia and hepatic steatosis in
diet-induced obese mice.
Methods: Male C57BL/6J mice (24-26 g) were divided into two groups (n = 10/group) and were fed a high-fat
diet containing 32% lard (control group) or 17% lard plus 15% pollock oil (experimental group) for 6 weeks. For
both groups, fat comprised 60% of the total caloric intake.
Results: Although body and liver masses for the two groups did not differ significantly, hepatic lipids
concentrations (triglycerides and total cholesterols) were lower (P < 0.05) after pollock oil ingestion. After 2 weeks
on the specified diets, plasma lipid levels (total cholesterol, LDL cholesterol, and triglycerides) significantly
decreased (P < 0.05) in the experimental group compared with the control group, although plasma HDL
cholesterol levels did not differ. At the end of 6 weeks, plasma adiponectin levels increased (P < 0.05), whereas
plasma resistin and leptin levels decreased (P < 0.05) in the experimental mice. Increased levels of long-chain
MUFAs and n-3 PUFAs in plasma, liver and adipose tissue by ingesting pollock oil were possibly correlated to these
favorable changes. Expression of hepatic genes involved in cholesterol metabolism (SREBP2, HMGCR, and ApoB) and
lipogenesis (SREPB1c, SCD-1, FAS, and Acaca) was suppressed in the experimental group, and may have favorably
affected hyperlipidemia and hepatic steatosis induced by the high-fat diet.
Conclusions: We demonstrated that pollock oil supplementation effectively improved hyperlipidemia, attenuated
hepatic steatosis, and downregulated the express of hepatic genes involved in cholesterol and lipid metabolism in
mice with diet-induced obesity.
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Background
Hyperlipidemia, a medical condition characterized by
increased blood levels of lipids including cholesterol and
triglycerides, is a critical component of metabolism syn-
drome as well as a possible predisposing factor for
atherosclerosis, a leading cause of death worldwide [1,2].
Lipids that accumulate in the arterial wall as a
consequence of hyperlipidemia are oxidized and attract
inflammatory monocytes, which differentiate into
m a c r o p h a g e st h a tt a k eu pt h eoxidized lipid. Oxidation
of low-density lipoproteins (LDLs) in the arterial wall is
a major and physiologically relevant mechanism for the
pathogenesis of atherosclerosis, and the presence of
lipid-loaded macrophage foam cells in the artery intima
is a predictor for the development of atherosclerotic
lesions. A close relationship exists between dietary fats
and dyslipidemia-related events [3]. Although an
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coronary heart disease, numerous studies have demon-
strated a protective effect of n-3 polyunsaturated fatty
acids (PUFAs) through a variety of mechanisms, includ-
ing reduction of triglycerides and very-low-density lipo-
proteins [4]. In addition, weh a v es h o w nt h a tm a r i n e -
derived long-chain monounsaturated fatty acids
(MUFAs) (i.e., C20:1 and C22:1 isomers) modulate
metabolic syndrome by restoring impaired glucose and
lipid metabolism [5]. Therefore, fish oils that are rich in
both n-3 PUFAs and long-chain MUFAs may help alle-
viate hypercholesterolemia and hypertriacylglyceridemia.
Alaska pollock (Theragra chalcogramma)i saN o r t h
Pacific species of the cod family, Gadidae. Pollock oil
contains considerable amoun t so fn - 3P U F A sa n dl o n g -
chain MUFAs [6]. The Alaska pollock fishing industry is
the largest in the United States and one of the largest in
the world. In recent years, pollock fishing has accounted
for ~30% of all U.S. seafood landings by mass [7].
Although pollock oil is used in both the food and feed
industries [8], little is known about the relationship
between dietary pollock oil and hyperlipidemia. Given
the health benefits of n-3 PUFAs and long-chain MUFAs,
we examined the effect of dietary pollock oil on hyperli-
pidemia in mice with diet-induced dyslipidemia.
Methods
Measurement of fatty acid composition of dietary oils
Cameria lard was purchased from Romi Smilfood B. V.
(Heerenveen, Netherlands). Pollock oil was obtained
from Nippon Suisan Kaisha, Ltd. (Tokyo, Japan) and
refined with silica gel and activated clays and then
steam-distillation deodorized. All standard and extracted
lipids were stored at -20°C until used. Fatty acid compo-
sitions of the dietary fats (Table 1) were determined
after methylation of samples with 14% (w/v) boron tri-
fluoride/methanol (Sigma Chemical Co., St. Louis,
USA.) at 80°C for 30 min. The resulting fatty acid
methyl esters were quantified by gas chromatography
using an Agilent 6890N Network Gas Chromatograph
System (Agilent Technologies Japan, Ltd., Tokyo, Japan)
equipped with a split injector, FID detector, and fused
silica capillary column (DB-WAX, 30 m × 0.25 mm I.D.
×0 . 2 5μm film thickness, J & W Scientific, Agilent
Technologies). Methyl esters were identified by compari-
son of retention times to those of fatty acid methyl ester
standards (Nu-Chek Prep, Inc., Elysian, MN, USA). Pol-
lock oil contains considerable levels of long-chain
MUFAs and n-3 PUFAs (C20:1 as well as C22:1 isomers
and n-3 PUFAs combined: ~ 45%).
Animals and diets
The Institutional Animal Care and Use Committee at
Nihon Bioresearch Inc. (Gifu, Japan) approved this
study. Male C57BL/6J mice (5 weeks old) were obtained
from Charles River Laboratories Japan Inc. (Yokohama,
Japan) and housed at Nihon Bioresearch at 23 ± 1°C
under a 12/12 h light-dark cycle. The animals were pro-
vided free access to water and standard mouse chow
CRF-1 (Oriental Yeast Co. Ltd., Tokyo, Japan) for a 1-
week acclimatization period.
After acclimatization, mice were randomly assigned to
one of two groups for the 6-week feeding experiment. The
control group (n = 10) was fed a high-fat diet containing
32% lard (D12492 Rodent Diet with 60 kcal% Fat; Research
Diets, Inc., NJ, USA) and the experimental group was fed a
diet supplemented with pollock oil (17% lard plus 15% pol-
lock oil). To control for total fat intake, the total fat content
in both diets corresponded to 60% of the caloric intake.
The compositions of the diets are listed in Table 2. Body
mass and food intake were monitored throughout the
study. At the end of the intervention period, mice were
Table 1 Fatty acid composition of dietary fats (%)
Fatty acid Lard Pollock oil
C14:0 1.5 4.9
C16:0 25.4 9.8
C16:1 2.4 6.1
C18:0 5.9 1.7
C18:1 40.6 14.3
C18:2 n-6 10.8 1.3
C18:3 n-3 1.0 1.1
C20:1 n-9 0.8 9.1
C20:1 n-7 ND 3.3
C22:1 n-11 ND 12.3
C22:1 n-9 ND 1.6
C20:5 n-3 0.02 10.3
C22:5 n-3 0.1 1.2
C22:6 n-3 0.03 7.9
Values correspond to mean of three separate samples processed
independently.
ND: Not detected.
Table 2 Diet compositions
Ingredient Lard diet (g/100 g diet) PO diet (g/100 g diet)
Casein 25.8 25.8
l-Cysteine 0.4 0.4
Maltodextrin 10 16.2 16.2
Sucrose 8.9 8.9
Cellulose 6.5 6.5
Mineral mixture 1.3 1.3
Vitamin mixture 1.3 1.3
Choline bitartrate 0.3 0.3
Soybean oil 3.2 3.2
Lard 32 17
Pollock oil – 15
PO diet: Pollock oil-supplemented diet.
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Page 2 of 10anesthetized with 4% sodium pentobarbital (Dainippon
Sumitomo Pharma, Osaka, Japan), and blood was collected
by abdominal vein puncture. Plasma was obtained by cen-
trifugation at 1000 g for 15 min and stored at -80°C until
analyses. Vital organs were removed and weighed after a
s h o r tw a s hi nc o l dp h o s p h a t e - b u f f e r e ds a l i n e ,p H7 . 4 .
Mesenteric white adipose tissue (WAT) and Livers were
kept at -80°C for the further lipid extraction and quantita-
tive polymerase chain reaction (QPCR) analysis.
Lipid extraction and fatty acid analysis
The fatty acid compositions of plasma, liver and WAT
in the C57BL/6J mice were determined as described
before [5]. Lipids were extracted by homogenizing the
tissue samples in a methanol/hexane solution (4:1 v/v)
added with butylated hydroxytoluene (BHT, 50 μg/mL)
as an antioxidant. The samples were methylated with
acetyl chloride, and the fatty acid methyl esters were
separated and quantified by gas chromatography. Identi-
f i c a t i o no ft h em e t h y le s t e r sw e r em a d eb yc o m p a r i s o n
of retention times of standard fatty acids.
Determination of plasma lipid levels
Blood samples were taken from the retro-orbital venous
plexus of each mouse at the end of weeks 0, 2, 4, and 6.
Plasma concentrations of triglyceride (TG), total choles-
terol (TC), and high-density lipoprotein (HDL) cholesterol
were measured using Triglycerol E-Test, Cholesterol E-
Test, and HDL-cholesterol E-Test kits (Wako Pure Che-
mical Industries, Ltd., Osaka, Japan), respectively. The
concentration of LDL cholesterol was calculated as [LDL
cholesterol] = [TC] - [HDL cholesterol] - [TG] × 0.2.
Determination of plasma adipokine levels
Plasma concentrations of adiponectin, resistin, and lep-
tin were determined at the end of the 6-week period
using the Mouse Adiponectin ELISA kit (Otsuka Phar-
maceutical Co., Ltd., Tokyo, Japan), Mouse Resistin
ELISA kit (Shibayagi Co. Ltd., Gunma, Japan), and
Mouse Leptin ELISA kit (Morinaga Institute of Biologi-
cal Science, Inc., Yokohama, Japan), respectively.
Determination of hepatic lipid levels
Total hepatic lipids were extracted from liver samples as
described [9]. Extracted lipids were dried under vacuum
(Concentrator Plus 5305, Eppendorf Inc., NY, USA) and
then dissolved in 2-propanol containing 10% (w/w) Tri-
ton X-100. Triglyceride and total cholesterol concentra-
tions were determined using the above-mentioned
commercial enzyme kits (Wako).
Determination of mRNA expression by QPCR
Total RNA was isolated from liver samples using TRIzol
reagent (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol. First-strand cDNA was gener-
ated from total RNA (1 μg) using the PrimeScript II 1st
strand cDNA Synthesis kit (TaKaRa Bio, Otsu, Japan).
The resulting cDNA was used for QPCR amplification
and specific sequence detection on an Applied Biosys-
tems 7300 Real-Time PCR System (Life Technologies
Ltd., Tokyo, Japan). The PCR cycling parameters were
30 s at 95°C; 40 cycles of 5 s at 95°C, 34 s at 60°C; and
a final melting curve of 15 s at 95°C, 1 min at 60°C, 15
s at 95°C. Gene expression was scaled to the expression
of the housekeeping gene encoding 18S ribosomal RNA.
PCR reactions contained forward and reverse primers
(10 μM each) and SYBR Premix Ex Taq (TaKaRa Bio).
The targeted genes, their corresponding proteins, and
the respective sense and antisense PCR primers were:
SREBP2 (sterol regulatory element binding protein 2),
5’- TGGGCGATGAGCTGACTCT-3’ and 5’-A C T G -
TAGCATCTCGTCGATGT-3’; HMGCR (3-hydroxy-3-
methylglutaryl-coenzyme A reductase), 5’- TGTTCACC
GGCAACAACAAGA-3’ and 5’-CCGCGTTATCGT-
CAGGATGA-3’; ApoB (apolipoprotein B), 5’-TTGGCA
AACTGCATAGCATCC-3’ and 5’-TCAAATTGG-
GACTCTCCTTTAGC-3’; ApoA (apolipoprotein A), 5’-
GGCACGTATGGCAGCAAGAT-3’ and 5’-CCAAG-
GAGGAGGATTCAAACTG-3’; SREBP1c (sterol regula-
tory element binding protein 1c), 5’-GATGTGC
GAACTGGACACAG-3’ and 5’-CATAGGGGGCGT-
CAAACAG-3’; SCD-1 (stearoyl-coenzyme A desaturase-
1), 5’-TTCTTGCGATACACTCTGGTGC-3’ and 5’-
CGGGATTGAATGTTCTTGTCGT-3’; FAS (fatty acid
synthase), 5’-TTCTTGCGATACACTCTGGTGC-3’ and
5’-CGGGATTGAATGTTCTTGTCGT-3’; Acaca
(acetyl-coenzyme A carboxylase alpha), 5’-GATGAAC-
CATCTCCGTTGGC-3’ and 5’-CCCAATTATGAATC
GGGAGTGC-3’.
Statistical analysis
Results are expressed as mean ± standard error of the
mean. Statistical differences between two groups were
analyzed by Student’s t-test and were considered signifi-
cant at P < 0.05.
Results
Effect of pollock oil on body and organ mass
Table 3 lists body and vital organ masses for diet-
induced obese C57BL/6J mice in the control (lard) and
experimental (pollock oil) groups. After the 6-week
feeding period, there were no significant differences in
body, liver, white as well as brown adipose tissue, and
skeleton muscle masses between the two groups.
Effect of pollock oil on plasma lipid levels
Compared to control, total cholesterol plasma levels for
the experimental group were reduced by 27% (P < 0.01),
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Page 3 of 1017% (P < 0.01), and 30% (P < 0.001) at the end of weeks
2, 4, and 6, respectively (Table 4). Pollock oil intake also
significantly reduced plasma LDL cholesterol levels by
33% (P < 0.05), 23% (P < 0.01), and 38% (P < 0.001),
and reduced plasma triglyceride levels by 40% (P <
0.01), 50% (P < 0.01), and 46% (P <0 . 0 1 )a tt h ee n do f
weeks 2, 4, and 6, respectively. No significant differences
in plasma HDL cholesterol levels were detected.
Effect of pollock oil on fatty acid compositions of plasma,
liver and WAT
Plasma, liver and mesentericW A Tf a t t ya c i dc o m p o s i -
tions in the control and pollock oil group are shown in
Table 5 and Table 6. Although total saturated fatty acid
levels did not differ between the control and experimen-
t a lg r o u p ,p o l l o c ko i li n g e s t i o nm a r k e d l y( P < 0.05)
increased long-chain MUFA (i.e., C20:1 and C22:1 iso-
mers combined) levels 3-, 1.2- and 5-fold in plasma, liver and WAT, respectively. Intake of pollock oil also
significantly (P < 0.05) increased total n-3 PUFA levels
3-, 2- and 7-fold in plasma, liver and WAT, respectively.
In contrast, total n-6 PUFA levels were significantly (P <
0.05) decreased by 50%, 31% and 14% in plasma, liver
and WAT, respectively in the pollock oil group as com-
pared to the control.
Effect of pollock oil on plasma adipocytokine levels
To determine if pollock oil could relieve the adipokine
dysregulation caused by excessive total caloric intake,
we measured the adipokine plasma levels. Intake of pol-
lock oil increased the plasma concentration of adiponec-
tin by 15% (P < 0.05) in the experimental group
compared to the control group (Figure 1A). Plasma
resistin and leptin concentrations were reduced by 14%
(P < 0.05) and 41% (P < 0.05), respectively (Figure 1B
and 1C).
Effect of pollock oil on hepatic steatosis
Because obesity can trigger hepatic steatosis, which is
associated with hyperlipidemia, we measured the levels
of hepatic lipids to determine if pollock oil suppressed
Table 3 Food intake, body mass, and vital organ masses
Lard diet PO diet
Food intake (g/day) 2.5 ± 0.03 2.3 ± 0.04
Initial body mass (g) 25.5 ± 0.4 25.5 ± 0.5
Final body mass (g) 32.7 ± 1.6 31.6 ± 2.4
Organ masses (mg/g body mass)
Liver 33.1 ± 0.7 33.6 ± 0.7
Epididymal WAT 50.9 ± 3.0 45.2 ± 3.9
Mesenteric WAT 15.4 ± 0.9 13.7 ± 1.1
Brown adipose tissue 3.3 ± 0.5 3.6 ± 0.3
Skeletal muscle 5.9 ± 0.4 5.9 ± 0.3
Each value represents the mean ± SE (n = 10). PO diet: Pollock oil-
supplemented diet; WAT: white adipose tissue.
Table 4 Plasma levels of total cholesterol, LDL
cholesterol, HDL cholesterol, and triglycerides
Lipids (mg/dL) Week 0 Week 2 Week 4 Week 6
Total
cholesterol
Lard diet 84.7 ± 7.1 154.5 ± 10.5 158.1 ± 4.5 161.5 ± 4.3
PO diet 80.8 ± 6.0 112.9 ± 3.7** 130.8 ± 5.7** 113.1 ± 2.7***
LDL
cholesterol
Lard diet 39.1 ± 7.0 83.5 ± 9.3 87.7 ± 3.4 78.5 ± 3.5
PO diet 38.1 ± 5.6 56.1 ± 3.1* 67.4 ± 5.4** 56.6 ± 2.5***
HDL
cholesterol
Lard diet 34.6 ± 2.0 54.4 ±2.8 51.4 ± 2.0 59.2 ± 2.5
PO diet 30.6 ± 2.4 47.3 ± 1.8 53.7 ± 2.7 43.7 ± 3.4
Triglycerides
Lard diet 56.4 ± 4.4 80.0 ± 10.1 95.7 ± 12.9 118.7 ± 19.8
PO diet 60.6 ± 4.9 47.7 ± 6.7** 48.2 ± 6.8** 63.9 ± 5.7**
Each value represents the mean ± SE (n = 10). PO diet: Pollock oil-
supplemented diet; LDL: low-density lipoprotein; HDL: high-density
lipoprotein; *P < 0.05; **P < 0.01; ***P < 0.001.
Table 5 Fatty acid composition in plasma (%)
Fatty acid Lard diet PO diet
14:0 0.20 ± 0.02 0.29 ± 0.02
16:0 13.95 ± 0.33 11.24 ± 1.17
18:0 8.68 ± 0.24 6.80 ± 0.86
SAF 22.84 ± 0.47 18.33 ± 2.03
12:1 23.68 ± 0.90 24.71 ± 1.84
16:1 0.69 ± 0.10 0.79 ± 0.08
18:1 9.23 ± 0.37 7.77 ± 0.52*
20:1 n-9 0.18 ± 0.01 0.24 ± 0.02*
20:1 n-7 ND 0.22 ± 0.02***
22:1 n-11 ND 0.17 ± 0.02**
22:1 n-9 ND 0.01 ± 0
MUFA 33.77 ± 0.97 33.91 ± 2.42
18:2 n-6 17.04 ± 0.25 10.81 ± 1.13**
18:3 n-6 0.26 ± 0.01 0.08 ± 0.01***
20:2 n-6 0.13 ± 0 0.07 ± 0.01*
20:3 n-6 0.89 ± 0.07 0.29 ± 0.04***
20:4 n-6 14.03 ± 0.57 3.61 ± 0.36***
22:4 n-6 0.02 ± 0 0.02 ± 0
n-6 PUFA 32.37 ± 0.38 14.87 ± 1.54***
18:3 n-3 0.18 ± 0.02 0.16 ± 0.02
20:5 n-3 0.40 ± 0.03 6.32 ± 0.81**
22:5 n-3 0.32 ± 0.07 4.71 ± 1.76**
22:6 n-3 5.11 ± 0.11 11.62 ± 2.04**
n-3 PUFA 6.01 ± 0.11 22.85 ± 2.18**
Each value represents the mean ± SE (n = 10). ND: Not detected; PO diet:
Pollock oil-supplemented diet; SAF: saturated fatty acids; MUFA:
monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; *P < 0.05; **P
< 0.01; ***P < 0.001.
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ide, and total cholesterol levels were reduced by 21% (P
< 0.01), 40% (P < 0.001), and 12% (P < 0.05), respec-
tively, in the experimental group compared with the
control group (Figure 2).
Effect of pollock oil on mRNA expression of genes
involved in hepatic lipid metabolism
The pollock oil-supplemented diet led to a 66% reduction
(P <0 . 0 0 1 )i nm R N Ae x p r e s s i o no fSREBP2,ag e n et h a t
encodes a transcription factor involved mainly in regula-
tion of cholesterol synthesis (Figure 3A). It also reduced
expression of the cholesterogenic gene HMGCR by 51%
(P < 0.05) and of ApoB by 23% (P < 0.05), although it had
no significant effect on expression of ApoA. Furthermore,
intake of pollock oil caused a 24% (P < 0.05) reduction in
mRNA expression of SREBP1c, which encodes for the
lipogenic transcription factor SREBP1c, and also reduced
expression of the downstream lipogenic genes SCD-1,
FAS,a n dAcaca by 68% (P < 0.001), 69% (P < 0.001), and
33% (P < 0.05), respectively (Figure 3B).
Discussion
People with obesity have an increased risk of cardiovas-
cular disease, which is a major cause of their increased
mortality. Although multiple factors are thought to con-
tribute to these elevated risks, one main determinant is
the adverse effect of obesity on lipoprotein levels [10].
For the study reported herein, we examined the effect of
pollock oil on dyslipidemia in diet-induced obese mice,
and showed that inclusion of pollock oil in a high-fat
diet significantly decreased plasma levels of total and
LDL cholesterol and triglyceride.
To identify possible mechanisms underlying this
reduction, we measured plasma adipokine levels. Adipo-
nectin, an adipocyte-derived hormone, is believed to
play an important role in regulating hyperglycemia,
hyperlipidemia, and endothelial dysfunction in humans,
all of which probably contribute to certain markedly
increased risks associated with obesity-related disorders,
e.g., atherosclerosis and diabetes [11]. Adiponectin levels
correlate negatively with serum triglyceride levels in
non-diabetic subjects and type-2 diabetics, and hypoadi-
ponectinemia is associated with smaller LDL particle
size, indicating a link between adiponectin and dyslipi-
demia [12-15]. Furthermore, in vitro data indicate that
adiponectin is an anti-inflammatory and anti-prolifera-
tive mediator that can modulate atherosclerosis progres-
sion [16-18]. Conversely, increased levels of
proinflammatory adipokines (e.g., tumor necrosis factor
a, resistin, monocyte chemotactic protein 1, and inter-
leukin 8) have been associated with increased serum
lipids (e.g., triglycerides, and total and LDL cholesterol),
which increase monocyte recruitment and adherence to
arterial walls, causing wall remodeling [19-22]. In addi-
tion, leptin, the first adipocytokine discovered, has been
associated with development of obesity, as ob/ob leptin-
deficient mice are markedly obese [23]. However, most
obese humans have increased blood leptin concentra-
tions, likely reflecting resistance to the action(s) of leptin
[ 2 4 ] .L e p t i ni sa l s oa s s o c i a t ed with increased insulin
resistance, which can cause hyperlipidemia [25]. There-
fore, the decreased plasma lipid concentrations observed
following pollock oil ingestion were possibly associated
with elevated plasma adiponectin levels and reduced
plasma proinflammatory adipokine levels. As endogen-
ous ligands for peroxisome proliferator-activated recep-
tors, n-3 PUFAs regulate the expression of genes
encoding key proteins involved in metabolism [26,27].
Intake of fish oil enriched in n-3 PUFAs has been
reported to increase plasma adiponectin levels and
lower proinflammatory adipokine levels [28,29]. Further-
more, we have shown that a diet rich in long-chain
MUFAs modulates adipokine profiles [5]. Fatty acid
composition analyses revealed that pollock oil ingestion
Table 6 Fatty acid composition in liver and mesenteric
WAT (%)
Fatty acid Liver Mesenteric WAT
Lard diet PO diet Lard diet PO diet
14:0 0.29 ± 0.01 0.30 ± 0.01 1.03 ± 0.03 1.85 ± 0.03*
16:0 21.47 ± 0.13 20.18 ± 0.24*** 20.43 ± 0.11 19.43 ± 0.23**
18:0 8.09 ± 0.13 10.06 ± 0.21*** 4.39 ± 0.11 5.02 ± 0.15**
SAF 29.85 ± 0.15 30.55 ± 0.17 25.85 ± 0.15 26.29 ± 0.22
12:1 7.37 ± 0.29 7.87 ± 0.28 2.11 ± 0.10 1.98 ± 0.09
16:1 1.46 ± 0.05 1.25 ± 0.07* 4.05 ± 0.21 3.94 ± 0.17
18:1 22.55 ± 0.35 13.58 ± 0.47*** 45.71 ± 0.15 37.42 ± 0.33***
20:1 n-9 0.51 ± 0.02 0.60 ± 0.02** 0.85 ± 0.03 3.12 ± 0.13***
20:1 n-7 ND 0.41 ± 0.01*** 0.15 ± 0 1.55 ± 0.05***
22:1 n-11 ND 0.19 ± 0.01*** 0.05 ± 0 1.37 ± 0.08***
22:1 n-9 0.06 ± 0 0.06 ± 0.01 0.04 ± 0 0.25 ± 0.01**
MUFA 32.05 ± 0.32 23.86 ± 0.51*** 52.95 ± 0.23 49.63 ± 0.51**
18:2 n-6 14.13 ± 0.28 11.89 ± 0.16*** 14.47 ± 0.17 12.70 ± 0.28***
18:3 n-6 0.29 ± 0.01 0.10 ± 0.03*** 0.07 ± 0 0.06 ± 0.01
20:2 n-6 0.22 ± 0 0.12 ± 0*** 0.27 ± 0 0.17 ± 0.03*
20:3 n-6 0.86 ± 0.04 0.47 ± 0.03*** 0.12 ± 0 0.06 ± 0***
20:4 n-6 9.31 ± 0.15 4.66 ± 0.09*** 0.24 ± 0.01 0.15 ± 0***
22:4 n-6 0.31 ± 0.01 0.03 ± 0*** 0.07 ± 0 0.03 ± 0***
n-6 PUFA 25.11 ± 0.18 17.26 ± 0.18*** 15.23 ± 0.17 13.17 ± 0.28***
18:3 n-3 0.45 ± 0.02 0.56 ± 0.03** 0.07 ± 0 0.96 ± 0.04***
20:5 n-3 0.29 ± 0.01 4.84 ± 0.17*** 0.10 ± 0 0.73 ± 0.05***
22:5 n-3 0.51 ± 0.01 1.66 ± 0.07*** 0.11 ± 0 0.44 ± 0.01***
22:6 n-3 6.32 ± 0.12 15.36 ± 0.26*** 0.18 ± 0 1.42 ± 0.04***
n-3 PUFA 7.55 ± 0.12 22.42 ± 0.18*** 0.45 ± 0.01 3.54 ± 0.12***
Each value represents the mean ± SE (n = 10). ND: Not detected; WAT: white
adipose tissue; PO diet: Pollock oil-supplemented diet; SAF: saturated fatty
acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids;
*P < 0.05; **P < 0.01; ***P < 0.001.
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Page 5 of 10Figure 1 Effect of pollock oil on plasma adipokine levels in mice fed a high-fat diet. Plasma levels of adiponectin (A), resistin (B), and
leptin (C) in C57BL/6J mice fed for 6 weeks with a diet containing 32% lard (lard diet) or 17% lard plus 15% pollock oil (PO diet). Values are
mean ± SE (n = 10). *P < 0.05.
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Page 6 of 10Figure 2 Effect of pollock oil on hepatic steatosis in mice fed a high-fat diet. Total hepatic lipid (A), triglyceride (B), and total cholesterol (C)
levels in C57BL/6J mice fed for 6 weeks with a diet containing 32% lard (lard diet) or 17% lard plus 15% pollock oil (PO diet). Values are mean ±
SE (n = 10). *P < 0.05; **P < 0.01; ***P < 0.001.
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Page 7 of 10Figure 3 Effect of pollock oil on transcription of genes related to hepatic cholesterol and lipid metabolism. mRNA levels for genes
involved in cholesterol (A) and lipid (B) metabolism in C57BL/6J mice fed for 6 weeks with a diet containing 32% lard (lard diet) or 17% lard
plus 15% pollock oil (PO diet). Values are mean ± SE (n = 10). *P < 0.05; ***P < 0.001.
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Page 8 of 10significantly increased long-chain MUFA and n-3 PUFA
levels in plasma and vital organs. Therefore, the favor-
able changes in the plasma adipokine profile might be
attributed to a combined effect of n-3 PUFAs and long-
chain MUFAs found abundantly in pollock oil.
Ingestion of pollock oil also decreased hepatic lipid
levels in the experimental group, indicating that pollock
oil inhibited hepatic steatosis triggered by obesity. The
liver is the most important organ in energy metabolism,
and is vital to the production and catabolism of plasma
lipoproteins and endogenous lipids [30,31]. The
improvement in fatty filtration in the livers of pollock
oil-fed mice was possibly related to the decreased
plasma lipid levels. To characterize how pollock oil
decreased hepatic lipid accumulation, we also deter-
mined the hepatic mRNA levels of genes related to lipid
metabolism. In the liver, sterol regulatory element-bind-
ing proteins (SREBPs) are key transcription factors that
regulate the levels of lipids produced for export into the
plasma as lipoproteins and into the bile as micelles. The
SREBP family includes SREBP1a, 1c, and 2 [32].
SREBP1c regulates transcription of genes involved in
fatty acid metabolism (e.g., SCD-1, FAS,a n dAcaca),
and SREBP2 regulates transcription of cholesterol-
related genes (e.g., HMGCR, which encodes the rate-
limiting enzyme of cholesterol biosynthesis). Increased
SREBP activity causes cholesterol and fatty acid accumu-
lation and downregulates the SREBP-cleavage-activating
protein (SCAP)/SREBP pathway by feedback inhibition
[33]. Our data show that, concomitant with downregula-
tion of SREBP1c and SREBP2 mRNA, intake of pollock
oil suppressed transcription of genes targeted by SREBP.
Furthermore, pollock oil intake inhibited hepatic ApoB
transcription. Apolipoprotein B is central in lipoprotein
metabolism [34], serving as a structural and functional
component of triglyceride-rich very-low-density lipopro-
teins and their metabolic products, e.g., intermediate-
density lipoprotein and LDL. Downregulation of ApoB
expression may therefore decrease circulating LDL cho-
lesterol levels. Notably, pollock oil ingestion did not
alter mRNA expression of ApoA, the structural compo-
nent of HDL, which may reflect the fact that plasma
HDL cholesterol levels were the same in the control and
experimental groups. Collectively, the observed
decreases in mRNA levels suggest that the improve-
ments in hepatic lipid levels and associated hyperlipide-
mia found in the experimental group may be partially
associated with decreased de novo cholesterol, lipid, and
ApoB synthesis.
Conclusions
Our study showed that ingestion of pollock oil amelio-
rated hypercholesterolemia and hypertriacylglyceridemia
in diet-induced obese mice. The hypolipidemic effect of
pollock oil was possibly related to an increase in plasma
adiponectin concentrations and a decrease in the plasma
levels of proinflammatory adipokines. Downregulation of
mRNA expression of lipogenic genes and genes involved
in cholesterol metabolism positively affected hepatic
lipid accumulation, which likely led to an improved
plasma lipid profile.
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